Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCH vs TCHL in HER-2 Positive Breast Cancer
NCT01485926Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Oct 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib in HER2-positive breast cancer (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Pathological Complete Response at 5 months. Started Oct 2010; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01485926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485926.